Brickell Biotech, Inc.

Brickell Biotech, Inc. is identified as a biotech company.

• 2022.02.01

  Reported2022.02.03

  Brickell Biotech acquires exclusive rights to Carna Biosciences’ autoimmune drug portfolio[2]Brickell Biotech取得Carna Biosciences自身免疫药物组合的独家权利bizwest.com

  Brickell Biotech announced that it acquired exclusive rights to develop and commercialize a portfolio of autoimmune drugs created by Carna Biosciences.

• 2021.06.25

  Reported2021.06.26

  Brickell and Kaken partner on Phase 1 gel study in Japan[3]Brickell与Kaken合作在日本开展凝胶一期研究bizwest.com

  Brickell Biotech and Kaken Pharmaceutical are partnering to launch the first phase of a study of pironium bromide gel in patients with primary palmoplantar hyperhidrosis in Japan.

Read more

1. 1brickellbio.combrickellbio.com
2. 2Brickell Biotech取得Carna Biosciences自身免疫药物组合的独家权利bizwest.com
3. 3Brickell与Kaken合作在日本开展凝胶一期研究bizwest.com